Condition: CNS Tumor · Solid Tumor · Sponsor: University Hospital Heidelberg
The aim of this trial is to determine preliminary activity of the combination treatment with nivolumab and entinostat in children and adolescents with high risk refractory/relapsed/progressive tumors harboring a high mutational load, focal MYC(N) amplification or ATRT-MYC subgroup as well as tumors with high tumor infiltrating lymphocytes (TILs) or a tertiary lymphoid structure (TLS).
This description comes directly from the study's public registry record.
Venukah Schäfer · +496221 56 7267 · venukah.schaefer@kitz-heidelberg.de
Melanie Heiß · +496221 56 7255 · melanie.heiss@kitz-heidelberg.de
Always discuss trial participation with your own doctor first.
| Sydney Children's Hospital | Randwick, New South Wales, Australia | Recruiting |
| Children's Hospital at Westmead | Westmead, New South Wales, Australia | Recruiting |
| Royal Children's Hospital | Parkville, Victoria, Australia | Recruiting |
| Perth Children's Hospital | Nedlands, Western Australia, Australia | Recruiting |
| St. Anna Children's Hospital | Vienna, Austria | Recruiting |
| Institut Curie | Paris, France | Recruiting |
| Augsburg University Hospital | Augsburg, Germany | Recruiting |
| Charité University Medicine Berlin | Berlin, Germany | Recruiting |
| Essen University Hospital | Essen, Germany | Recruiting |
| Hannover Medical School | Hanover, Germany | Recruiting |
| Hopp Children's Cancer Center Heidelberg (KiTZ) | Heidelberg, Germany | Recruiting |
| Prinses Máxima Centrum | Utrecht, Netherlands | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03838042